Mineralys Therapeutics Statistics
Total Valuation
MLYS has a market cap or net worth of $665.34 million. The enterprise value is $374.12 million.
Important Dates
The next estimated earnings date is Tuesday, November 5, 2024, after market close.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MLYS has 49.73 million shares outstanding. The number of shares has increased by 132.69% in one year.
| Shares Outstanding | 49.73M |
| Shares Change (YoY) | +132.69% |
| Shares Change (QoQ) | +9.92% |
| Owned by Insiders (%) | 2.55% |
| Owned by Institutions (%) | 48.68% |
| Float | 23.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.36 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.20
| Current Ratio | 11.20 |
| Quick Ratio | 10.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.62% and return on invested capital (ROIC) is -29.24%.
| Return on Equity (ROE) | -41.62% |
| Return on Assets (ROA) | -27.58% |
| Return on Capital (ROIC) | -29.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.27M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +65.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +65.43% |
| 50-Day Moving Average | 12.66 |
| 200-Day Moving Average | 12.68 |
| Relative Strength Index (RSI) | 50.04 |
| Average Volume (20 Days) | 126,757 |
Short Selling Information
The latest short interest is 1.61 million, so 3.24% of the outstanding shares have been sold short.
| Short Interest | 1.61M |
| Short Previous Month | 1.59M |
| Short % of Shares Out | 3.24% |
| Short % of Float | 6.77% |
| Short Ratio (days to cover) | 11.47 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -134.51M |
| Pretax Income | -90.80M |
| Net Income | -119.67M |
| EBITDA | n/a |
| EBIT | -134.51M |
| Earnings Per Share (EPS) | -$2.74 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 311.12M |
| Total Debt | n/a |
| Net Cash | 311.12M |
| Net Cash Per Share | $6.26 |
| Equity (Book Value) | 290.10M |
| Book Value Per Share | 5.84 |
| Working Capital | 289.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$97.30 million and capital expenditures -$59,000, giving a free cash flow of -$97.36 million.
| Operating Cash Flow | -97.30M |
| Capital Expenditures | -59,000 |
| Free Cash Flow | -97.36M |
| FCF Per Share | -$1.96 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |